Your partner in radiopharmacy

Since 2004, Trasis designs, manufactures,  sells and supports high performance synthesizers, dose preparation and dispensing equipment, all related consumables and shielding solutions

Products

Helping the medical community easily access new radiolabeled therapeutic and diagnostic substances.

Our nuclear medicine equipment includes automated synthesizers, dose dispensing systems, their shielding and accessories. We also develop customized synthetic methods and instruments adapted to the evolving needs of the radiochemistry industry.

Our equipment is used worldwide in nuclear medicine departments, research centers, radiopharmaceutical production facilities and pharmaceutical companies.

See all products

About us

In a  nutshell: designer and manufacturer of radiopharma instruments, ISO 9001-certified company, medical device distributor, close to its customers and partners.

What makes us different: we consider our customers' performance as our own and we put everything in place to improve it.

Our strength:  every aspect of our products: design, manufacturing, commercial service, quality and support is under our full control. Our great multidisciplinary team makes this possible.

Our final goal: enable patients to have access to a wide range of radiotracers in the safest and most timely manner.

Read more

Innovating for nuclear medicine

We develop innovating equipment which enables safe manipulation and quick access to radiolabeled therapeutic and diagnostic substances.

Nuclear Medecine  departements

Drug developers

Drug developers

Nuclear medicine departments

Drug manufacturers

Drug manufacturers

After sales services
After Sales services
Mail US
support_trasis [at] trasis [dot] com

News & Events

TRASIS offers the widest range of PSMA tracers to be produced on the same synthesizer.

Düsseldorf, 15 October 2018.

Prostate cancer is the second leading cause of cancer death for men in many parts of the world. For imaging, PSMA-based radio tracers target the PSMA  (Prostate Specific Membrane Antigen) transmembrane glycoprotein, which is strongly upregulated in prostate cancer cells. In this way, the PET tracer provides important molecular information on cancer and metastases localization within the prostate.

AllinOne family versatility proven

TRASIS EUROPE | ONE MORE SUCCESS FOR TRASIS’ FDG DUAL MARKET AUTHORIZATION

Three months after its approval by the American FDA, Trasis’ FDG Dual method obtains its Market Authorization for Belgium and the Netherlands.

Trasis and Radboud Translational Medicine (RTM) worked together and finalized the Marketing Authorization National Phase for FDG production on AllinOne synthesizers.

TRASIS EUROPE | NEW LOCAL PARTNER, MORE PROXIMITY

Ans, 11 October 2018 – We are pleased to announce that we have entered into an agreement with RQS. Ruffani Quality Solutions will be our agent and provide service support for Germany and Austria.

With decades of experience and jointly to Trasis, RQS are committed to listening to our customers in order to provide the most effective solution. Located in Heideneau, RQS is also a valued partner and able to offer technical support in Germany and Austria.

Scientific Publications

Key facts

>35
Global partners
>30
Approved or demonstrated tracers
90%
exposure reduction
10 Years
Extended warranty for dispensers